Lilly expands multimedia efforts with YouTube channel
INDIANAPOLIS — A few months after launching its multichannel platform to inform and educate patients about healthy eating, physical activity and stress management, drug maker Eli Lilly has debuted a new YouTube channel.
The Lilly Health Channel features videos on health and wellness, employee and community outreach efforts, health innovation, Lilly programs and other nonproduct-branded initiatives. Some of the issues spotlighted in the videos include the growing rate of diabetes in the United States, Lilly’s Connecting Hearts Abroad global service program and more.
"Every day, we make an impact on the lives of patients through our medicines, but there are also many other ways we are connecting with patients through programs, education and outreach," said Jack Harris, Lilly’s VP U.S. medical division. "The Lilly Health Channel enables us to tell those stories through video in a way that reaches and engages patients like we never have before."
The Lilly Health Channel also will direct visitors to:
Lilly for Better Health, a program that educates and inspires individuals, families and communities to live healthier, more active lives;
LillyPad, the drug maker’s official blog, which enables a dialogue with the public on matters important to Lilly and those following the biopharmaceutical industry; and
Health Education Answers, an online health education program designed to help improve patient care through education outreach.
Supervalu to sell 107 fuel centers
EDEN PRAIRIE, Minn. — Supervalu has announced the sale of 107 fuel centers located in the Midwest, Intermountain West and West Coast regions following the acceptance of four separate bids to purchase the centers. The transactions include the majority of fuel centers within the Albertsons, Cub Foods, Hornbacher’s and Jewel-Osco banners.
The transactions, expected to be finalized this fall, will allow Supervalu to monetize noncore assets, creating capital that the company can use to further strengthen its business, the company reported. The transactions also include partnership opportunities that will result in Supervalu continuing to have the ability to offer fuel rewards programs to its customers through these existing fuel centers, and in most markets, through an expanded network of fuel centers.
“As we execute on our strategic plan, we are continually reviewing all areas of our business to identify opportunities to strengthen our market position, reduce costs or generate capital that can be reinvested into the business,” Supervalu EVP retail operations Pete Van Helden said. “These transactions help us further execute on our transformation plan, while also creating an opportunity for us to partner with major fuel retailers to bring broader fuel rewards programs to our customers.”
Specific transaction details are as follows:
Tesoro will purchase 51 Albertsons fuel centers located in California, Nevada, Oregon, Utah, Washington, Wyoming and Idaho;
Couche-Tard/Circle K will purchase 27 Jewel-Osco fuel centers, primarily in the Chicagoland area;
Holiday Stationstores will purchase 15 fuel centers — eight from Cub Foods in Minnesota, two from Hornbacher’s in North Dakota and five from Albertsons in Montana; and
Stinker will purchase 14 Albertsons fuel centers in Southern Idaho.
Supervalu currently operates a total of 134 fuel centers across its operations. The company will continue to operate 27 fuel centers not involved in these transactions, while continuing to seek potential buyers moving forward.
Boehringer Ingelheim, Eli Lilly present data from studies of diabetes drugs
RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.
The drug makers will make seven presentations, including study results evaluating linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, as well as empagliflozin (BI-10773), an investigational sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor. Additionally, a long-term study evaluating the efficacy and safety of linagliptin in patients with Type 2 diabetes was selected by EASD as an oral presentation.
Linagliptin in the 5-mg strength was approved in May by the Food and Drug Administration under the trade name Tradjenta.